Mathers Edward T Buys Nearly 10,000 Shares of Rhythm Pharmaceuticals, Signaling Strong Confidence Ahead of Setmelanotide FDA Decision.

Insider Buying by Mathers Signals Confidence in Rhythm’s Pipeline On March 2 2026, Mathers Edward T (through the Mathers Revocable Trust) purchased 4,198 shares of Rhythm Pharmaceuticals common stock—bringing his holdings to 9,969 shares—at no cash consideration as part of a pro‑rata distribution from NEA Partners 13. The transaction is a “buy” that reflects a long‑term stake rather than a short‑term speculation. Rhythm’s share price hovered around $90, and the trade’s 0 % price change and modest 66 % buzz indicate that the market viewed it as a routine, confidence‑driven move.

What This Means for Investors Mathers’ purchase comes after a modest sell of 4,000 restricted‑stock units in June 2025, suggesting he is consolidating rather than divesting. The buy aligns with Rhythm’s recent Phase 3 successes and a pending FDA decision on setmelanotide, a drug that could unlock a multi‑billion dollar revenue stream. For shareholders, the move is a subtle green flag that insiders see value beyond the current 16‑month decline. Analysts who have tempered their price targets may still view the stock as a long‑term play, especially as the company moves from trial to commercialization.

Mathers Edward T Profile Mathers has a history of buying common stock when the company is in a growth phase and selling restricted‑stock units when the company’s valuation peaks. In June 2025, he bought 4,000 shares and sold an equal amount of restricted units, a pattern that repeats in 2026 when he adds to his position without cash. His holdings have steadily grown from 5,771 shares in mid‑2025 to nearly 10,000 shares today, indicating a belief in Rhythm’s strategic trajectory. The lack of any large cash outlay in the March trade underscores his confidence in the company’s future cash flow rather than a short‑term market play.

Insider Activity in Context While Rhythm’s CFO and other executives have been busy trading shares—often selling to fund compensation or manage tax exposure—Mathers’ activity stands out as a net purchase. This contrast may suggest that while senior management is managing liquidity, long‑term investors like Mathers are positioning for a roll‑out of setmelanotide and the anticipated revenue lift. In a sector where timing is critical, such insider buying can be a meaningful signal for the market, especially when accompanied by robust clinical data and a favorable regulatory outlook.